Focus on Lymphoma & Myeloma
Volume 4, Issue 4.1
This supplement features a look at controversies in myeloma treatment, the future of immunotherapy for lymphoma, newly approved and investigational therapies, and more.
Table of Contents
Newly Approved Drugs
The Year in FDA Approvals
In 2017, the U.S. Food and Drug Administration (FDA) approved several therapies for the treatment of lymphoid malignancies, including the first two chimeric antigen...
In the Pipeline
The Lymphoid Malignancies Pipeline
Below is a list of agents under investigation for the treatment of lymphoid malignancies. Information was gathered from ClinicalTrials.gov, as well as the respective...
Features
Controversies in Myeloma: The Who, When, and Why of Treatment
The recent expansion of treatment options for patients with multiple myeloma (MM) has introduced new opportunities for redefining the goals of therapy. At the...
Immunotherapy: Exploring the Next Frontier for Non-Hodgkin Lymphoma Treatment
When the U.S. Food and Drug Administration approved the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel for the treatment of relapsed or refractory...
Meeting News
A Curative Strategy for High-Risk Smoldering Multiple Myeloma?
In a phase II trial of patients with previously untreated smoldering multiple myeloma (SMM), the combination of carfilzomib, lenalidomide, and dexamethasone, followed by autologous...
Final Analysis of IFM2009 Trial Confirms Predictive Value of Minimal Residual Disease in Myeloma
Because survival for patients with multiple myeloma (MM) has significantly improved within the past decade, complete response (CR) rates may no longer be a...
Final ASPIRE Results Confirm Survival Benefit With Carfilzomib Plus Lenalidomide and Dexamethasone in Relapsed/Refractory...
According to final results from the phase III ASPIRE study assessing patients with relapsed/refractory multiple myeloma (MM), adding the proteasome inhibitor carfilzomib to a...
Doubling Down on Double Transplant for Myeloma: Updated Results from EMN02/H095
More than a year ago, at the 2016 ASH Annual Meeting, Michele Cavo, MD, from the Serágnoli Institute of Hematology at Bologna University School...
BCMA Antibody Drug Conjugate Active in Patients With Heavily Pretreated Myeloma
In a phase I study presented at the 2017 ASH Annual Meeting, 60 percent of patients with heavily-pretreated multiple myeloma (MM) responded to treatment...
Early-Phase Study Finds Venetoclax Plus Obinutuzumab Safe and Effective in Patients with Untreated CLL
Venetoclax – a highly selective, potent BCL2 inhibitor – demonstrated significant anti-tumor activity in patients with chronic lymphocytic leukemia (CLL), both as monotherapy and...
For Patients With Plasma Cell Disorders, Are Two Flu Vaccines Better Than One?
Patients with plasma cell disorders (PCDs) such as multiple myeloma (MM) have compromised immunity, and potent anti-cancer treatments further deplete immunity, making them highly...
Brentuximab Vedotin Plus R-CHP a Frontline Treatment Option for Patients with NHL Subtypes
The CD30-directed immunoconjugate brentuximab vedotin has demonstrated efficacy in Hodgkin lymphoma (HL) and other T-cell lymphomas. According to research presented at the 2017 ASH...
Addition of Rituximab to High-Dose Chemotherapy Does Not Improve Response in Patients With Central...
According to results of an international, randomized, phase III trial, combining rituximab with high-dose, methotrexate-based chemotherapy did not improve response rates or survival for...
Daratumumab Shows Efficacy in Previously Treated Systemic Light-Chain Amyloidosis
Daratumumab, an anti-CD38 monoclonal antibody indicated for the treatment of patients with multiple myeloma (MM), has also shown efficacy in patients with systemic light-chain...
CC-122 Plus Obinutuzumab: An Effective, Chemotherapy-Free Regimen for Non-Hodgkin Lymphoma?
Results from a phase Ib study of CC-122 (an oral agent that binds the cereblon ubiquitin ligase complex), in combination with obinutuzumab, showed positive...
A New BTK Inhibitor on the Block: Zanubrutinib Demonstrates High Activity in Aggressive Non-Hodgkin...
Zanubrutinib (BGB-3111) is a potent, highly specific, and irreversible Bruton tyrosine kinase (BTK) inhibitor that is effective in treating aggressive B-cell malignancies, according to...
